Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
12 mars 2025 07h30 HE
|
Sagimet Biosciences Inc.
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of...
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
11 mars 2025 08h00 HE
|
Sagimet Biosciences Inc.
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet...
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
19 févr. 2025 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
06 janv. 2025 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
26 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
18 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and conventional pathology demonstrated...
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
14 nov. 2024 08h00 HE
|
Sagimet Biosciences Inc.
Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology Successful...
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
07 nov. 2024 07h30 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
29 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety and efficacy of denifanstat in patients...
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
16 oct. 2024 07h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...